Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53)
✍ Scribed by Prakash B. Chougule; Muhammad S. Akhtar; Ritesh Rathore; James Koness; Robert McRae; Peter Nigri; Kathie Radie-Keane; Teresa Kennedy; Harold J. Wanebo; Neal Ready
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 127 KB
- Volume
- 30
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background.
A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer.
Methods.
Forty‐three patients (stage III, n = 12; stage IV, n = 31) were treated with 8 cycles of weekly paclitaxel (60 mg/m^2^), carboplatin (area under the curve [AUC] = 1), and RT (1.8 Gy daily; total dose, 66–72 Gy). Patients with initially palpable lymph nodes underwent neck dissection.
Results.
The overall clinical response rate was 91% (65% complete, 26% partial). Severe mucositis occurred in 37 (90%) patients, necessitating hospitalization in 13 (31%) patients. With a median follow‐up of 49 months, the locoregional and distant failure rates were 26% and 21%, respectively.
Conclusions.
Concurrent paclitaxel, carboplatin, and RT for advanced head and neck cancer results in high complete response rates. Long‐term follow‐up has revealed the curative potential of this regimen, though the doses used resulted in unacceptable toxicity. © 2007 Wiley Periodicals, Inc. Head Neck 2008